PL4233858T3 - Wzmacnianie autofagii lub wydłużanie życia poprzez podawanie urolityn lub ich prekursorów - Google Patents

Wzmacnianie autofagii lub wydłużanie życia poprzez podawanie urolityn lub ich prekursorów

Info

Publication number
PL4233858T3
PL4233858T3 PL23175506.7T PL23175506T PL4233858T3 PL 4233858 T3 PL4233858 T3 PL 4233858T3 PL 23175506 T PL23175506 T PL 23175506T PL 4233858 T3 PL4233858 T3 PL 4233858T3
Authority
PL
Poland
Prior art keywords
urolithins
precursors
administration
increasing longevity
enhancing autophagy
Prior art date
Application number
PL23175506.7T
Other languages
English (en)
Polish (pl)
Inventor
Christopher L. Rinsch
William BLANCO-BOSE
Bernard Schneider
Laurent MOUCHIROUD
Dongryeol RYU
Penelope Andreux
Johan Auwerx
Original Assignee
Amazentis Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48782652&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL4233858(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amazentis Sa filed Critical Amazentis Sa
Publication of PL4233858T3 publication Critical patent/PL4233858T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/132—Amines having two or more amino groups, e.g. spermidine, putrescine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/366—Lactones having six-membered rings, e.g. delta-lactones
    • A61K31/37—Coumarins, e.g. psoralen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/525—Isoalloxazines, e.g. riboflavins, vitamin B2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/18—Antioxidants, e.g. antiradicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/78—Ring systems having three or more relevant rings
    • C07D311/80—Dibenzopyrans; Hydrogenated dibenzopyrans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Molecular Biology (AREA)
  • Rheumatology (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dermatology (AREA)
  • Addiction (AREA)
  • Psychology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
PL23175506.7T 2012-06-27 2013-06-27 Wzmacnianie autofagii lub wydłużanie życia poprzez podawanie urolityn lub ich prekursorów PL4233858T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261665137P 2012-06-27 2012-06-27
US201261712886P 2012-10-12 2012-10-12
US201361791137P 2013-03-15 2013-03-15

Publications (1)

Publication Number Publication Date
PL4233858T3 true PL4233858T3 (pl) 2025-06-09

Family

ID=48782652

Family Applications (1)

Application Number Title Priority Date Filing Date
PL23175506.7T PL4233858T3 (pl) 2012-06-27 2013-06-27 Wzmacnianie autofagii lub wydłużanie życia poprzez podawanie urolityn lub ich prekursorów

Country Status (16)

Country Link
US (11) US11020373B2 (enExample)
EP (3) EP4566677A3 (enExample)
JP (5) JP6422163B2 (enExample)
KR (5) KR102163091B1 (enExample)
CN (2) CN105142632B (enExample)
AR (1) AR091604A1 (enExample)
AU (6) AU2013284419A1 (enExample)
BR (1) BR112014032809A8 (enExample)
CA (3) CA3127211C (enExample)
DK (1) DK4233858T3 (enExample)
ES (2) ES3032009T3 (enExample)
MX (3) MX393128B (enExample)
PL (1) PL4233858T3 (enExample)
PT (2) PT2866804T (enExample)
SG (3) SG10202106329TA (enExample)
WO (1) WO2014004902A2 (enExample)

Families Citing this family (89)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2866804T (pt) * 2012-06-27 2023-12-18 Amazentis Sa Melhoria da autofagia ou aumento da longevidade por administração de urolitinas ou seus precursores
AU2014206777A1 (en) * 2013-01-18 2015-07-09 Procell Sprl Urolithin B for muscle growth
WO2015035358A1 (en) * 2013-09-09 2015-03-12 Natreon, Inc. Regulation of steroidogenic activity by using purified shilajit
EP2862568A1 (en) * 2013-10-15 2015-04-22 Centre National de la Recherche Scientifique (CNRS) Compositions comprising urolithins and uses thereof for the stimulation of insulin secretion
CA2972013C (en) 2013-12-23 2020-04-28 Amazentis Sa Process-scale synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
GB201413228D0 (en) 2014-07-25 2014-09-10 Nugerontix Ltd Polyphenol compositions
US20170367390A1 (en) * 2014-12-19 2017-12-28 Halo Life Science, Llc Use of ellagic acid dihydrate in food products and nutraceuticals
CN107531606A (zh) * 2015-04-13 2018-01-02 住友精化株式会社 2‑卤代苯甲酸类的制造方法
JP6740548B2 (ja) * 2015-05-15 2020-08-19 公立大学法人岡山県立大学 ウロリチン類を含有する育毛剤、及び、ウロリチン類を含有する５αレダクターゼ活性阻害剤
JP2017014154A (ja) * 2015-07-01 2017-01-19 公立大学法人岡山県立大学 ウロリチン類を含有するヒアルロン酸産生促進剤
JP6799767B2 (ja) * 2015-07-07 2020-12-16 公立大学法人岡山県立大学 ウロリチン類を含有するメラニン産生抑制剤
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
EP3393467B1 (en) * 2015-12-24 2020-07-01 Amazentis SA Compositions comprising nicotinamide riboside and a urolithin
JP2017210444A (ja) * 2016-05-26 2017-11-30 株式会社ダイセル ウロリチン類を含有するリパーゼ阻害剤
JP6791478B2 (ja) * 2016-05-26 2020-11-25 株式会社ダイセル ウロリチン類を含有するアンジオテンシン変換酵素阻害剤
EP3478091B1 (en) * 2016-06-29 2024-03-20 Halo Life Science, LLC Method of preparing a low odor dicholinium ellagate salt and other low odor organic salts of choline
EP3481411A4 (en) 2016-07-11 2020-07-22 University of North Texas Health Science Center at Fort Worth TREATING GLAUCOMA AND OTHER EYE DISEASES
US11634686B2 (en) 2016-11-01 2023-04-25 Jian Feng Method of producing naive pluripotent stem cells
EP3354645A1 (en) 2017-01-26 2018-08-01 Patheon Austria GmbH & Co KG Process for preparing urolithins
EP4553071A3 (en) 2017-03-08 2025-07-23 Amazentis SA Methods for improving mitophagy in subjects
US11969408B2 (en) 2017-03-08 2024-04-30 Amazentis Sa Method for improving mitophagy in subjects
EP3592347A1 (en) 2017-03-08 2020-01-15 Amazentis SA Skin treatment methods
JP2019097566A (ja) * 2017-12-07 2019-06-24 大正製薬株式会社 体内時計調整用組成物
CA3086321A1 (en) * 2017-12-20 2019-06-27 Societe Des Produits Nestle S.A. Compositions and methods using high protein for induction of autophagy
CA3086250A1 (en) * 2017-12-20 2019-06-27 Societe Des Produits Nestle S.A. Compositions and methods using a combination of autophagy inducer and high protein for induction of autophagy
WO2019160588A1 (en) * 2018-02-19 2019-08-22 Natreon, Inc. Synergistic combinations of urolithins a and b for improving cognitive capacity or cognitive function
WO2019163176A1 (ja) 2018-02-21 2019-08-29 株式会社ダイセル ウロリチン類を含有する破骨細胞分化抑制剤
CN112074510A (zh) * 2018-02-27 2020-12-11 阿马曾提斯公司 尿石素a的工业规模合成
WO2019187918A1 (ja) * 2018-03-29 2019-10-03 国立大学法人 琉球大学 分化コントロール化合物を用いて造腫瘍性をもつおそれのある未分化ｉＰＳ細胞等の混入を除去する方法
MX2020011619A (es) * 2018-04-30 2021-01-15 Amazentis Sa Urolitina como mejorador inmunitario.
US20210267932A1 (en) 2018-05-15 2021-09-02 University Of Louisville Research Foundation, Inc. Compounds, compositions, methods of using, and methods for preparing compounds
EP3801496A4 (en) 2018-06-05 2022-07-06 Flagship Pioneering Innovations V, Inc. SUBSTANCES AND METHODS OF USE FOR THE TREATMENT OF METABOLIC DISEASES AND NON-ALCOHOL FATTY LIVER
WO2019236765A1 (en) * 2018-06-05 2019-12-12 Flagship Pioneering Innovations V, Inc. Acylated catechin polyphenols and methods of their use for the treatment of cancer
CN108676013B (zh) * 2018-06-25 2021-01-01 中国医学科学院医药生物技术研究所 具有自噬激活活性的黄醇酮类化合物、其制备方法及其制药应用
CN109316478A (zh) * 2018-11-06 2019-02-12 上海出入境检验检疫局动植物与食品检验检疫技术中心 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品
PL245399B1 (pl) 2018-11-29 2024-07-15 Univ Warszawski Medyczny Kompozycja farmaceutyczna zawierająca urolitynę A lub jej pochodną do zastosowania zewnętrznego miejscowego w leczeniu, hamowaniu i zapobieganiu chorobom skóry i błon śluzowych o podłożu zapalnym
US20220241240A1 (en) * 2019-01-18 2022-08-04 Societe Des Produits Nestle S.A. Agents and methods for increasing stem cell function
CN110066284B (zh) * 2019-02-01 2021-06-04 贵阳倍隆生物科技有限公司 一种一锅法合成鞣花酸的方法
CN110229167B (zh) * 2019-05-22 2020-11-24 珠海萱嘉君行健康产业发展有限公司 一种利用五倍子制备鞣花酸的方法、制得的鞣花酸及其应用
CN111995610A (zh) * 2019-05-27 2020-11-27 首都医科大学 一种尿石素类化合物用于治疗胶质母细胞瘤药物的应用
US20200397807A1 (en) * 2019-06-18 2020-12-24 MitoPower, LLC Nicotinyl riboside compounds and their uses
US20220184015A1 (en) * 2019-06-20 2022-06-16 Societe Des Produits Nestle S.A. Compositions and methods to potentiate musculoskeletal effect of one or more anabolic amino acids on bone health
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
GB201915191D0 (en) * 2019-10-21 2019-12-04 Floratek Gmbh Novel heterocyclic compounds
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
CN114727980A (zh) * 2019-11-27 2022-07-08 雀巢产品有限公司 苯并香豆素ampk活化剂化合物、组合物、方法及其用途
JP2023503276A (ja) * 2019-11-27 2023-01-27 ソシエテ・デ・プロデュイ・ネスレ・エス・アー Ａｍｐｋ間接活性化化合物と組み合わせたａｍｐｋ直接活性化化合物、組成物、方法、及びそれらの使用
CN113018305A (zh) * 2019-12-24 2021-06-25 兰州大学 一种化合物在制备治疗阿尔兹海默症药物中的应用
CA3168493A1 (en) * 2020-02-20 2021-08-26 The Royal Institution For The Advancement Of Learning/Mcgill University Use of castalagin or analogs thereof for anti-cancer efficacy and to increase the response to immune checkpoint inhibitors
EP4182342A4 (en) * 2020-07-17 2024-08-14 The Trustees of Columbia University in the City of New York Methods and compositions to increase lifespan and healthspan by mimicking the effects of time-restricted feeding
CN111983058B (zh) * 2020-07-30 2023-06-23 云南中医药大学 中药抗非酒精性脂肪肝活性物质的筛选方法
WO2022051643A1 (en) * 2020-09-04 2022-03-10 Natreon, Inc. Methods of treating and preventing hepatotoxicity
AU2021346837A1 (en) 2020-09-25 2023-03-02 Société des Produits Nestlé S. A. Compositions and methods using xanthan gum to stabilize at least one urolithin in an aqueous matrix
KR102623664B1 (ko) 2020-12-10 2024-01-12 서울대학교산학협력단 유로리틴 a를 이용한 당뇨성 알츠하이머병의 치료 조성물 및 치료 방법
US11820751B2 (en) 2021-01-27 2023-11-21 Vandria Sa Urolithin derivatives and methods of use thereof
CN112716938A (zh) * 2021-02-25 2021-04-30 新疆医科大学 鞣花酸在制备缓解眼组织病变的药物中的用途
KR102677423B1 (ko) * 2021-09-17 2024-06-21 조선대학교산학협력단 망기페린을 포함하는 자가포식 활성화용 조성물
KR102690860B1 (ko) * 2021-10-13 2024-08-05 한국해양과학기술원 남극 진균 균주 Pleosporales sp. SF-7343 유래 대사화합물을 포함하는 염증질환 예방 또는 치료용 조성물
WO2023073079A1 (en) * 2021-10-28 2023-05-04 Société des Produits Nestlé S.A. Compositions and methods using a combination of nutrients to support cognition and emotional health in a mammal
US20230277669A1 (en) 2022-02-24 2023-09-07 Amazentis Sa Uses of urolithins
AU2023237544A1 (en) 2022-03-22 2024-10-31 Amazentis Sa Compositions
JP2025521186A (ja) * 2022-06-06 2025-07-08 アマゼンティス エスアー 心臓機能および健康を改善するためのウロリチン
CN119947717A (zh) * 2022-07-27 2025-05-06 范徳利亚股份公司 尿石素衍生物的治疗用途
CN115433151A (zh) * 2022-09-02 2022-12-06 苏州大学 一种6，7，8-三羟基香豆素的制备方法
CN115581689B (zh) * 2022-10-17 2024-05-14 常州大学 尿石素b酰胺类衍生物的应用
GB202219317D0 (en) 2022-12-20 2023-02-01 Amazentis Sa Methods for improving mitophagy in subjects
GB202308224D0 (en) 2023-06-01 2023-07-19 Amazentis Sa Formulation
CN116966188B (zh) * 2023-07-14 2026-04-03 天津医科大学总医院 丁香素在制备治疗和/或预防炎症性肠病药物中的应用
GB202312220D0 (en) 2023-08-09 2023-09-20 Amazentis Sa Formulation
WO2025076497A1 (en) * 2023-10-06 2025-04-10 Northeast Ohio Medical University Combination treatment of tau pathology
FR3153998A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d’iso-urolithine A sur une peau sensible
FR3153997A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d'au moins l’urolithine B sur une peau sensible
FR3153996A1 (fr) * 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d'au moins l’urolithine C sur une peau sensible
EP4791374A1 (en) * 2023-10-13 2026-08-19 L'oreal Cosmetic use of at least urolithin b or c on a sensitive skin
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
CN117643586A (zh) * 2023-11-16 2024-03-05 中国航天员科研训练中心 尿石素a用于调节生物节律的用途
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use
CN117771237B (zh) * 2024-02-27 2024-05-03 南昌医学院 一种松香烷型二萜化合物的用途和制备方法
WO2025194036A1 (en) * 2024-03-14 2025-09-18 Washington University Autophagy enhancers
WO2025224366A1 (en) 2024-04-26 2025-10-30 Amazentis Sa Immune health improvers
WO2025252771A1 (en) 2024-06-03 2025-12-11 Amazentis Sa Urolithin combinations
WO2025264604A1 (en) * 2024-06-17 2025-12-26 The Procter & Gamble Company Skin care composition and method of using the same
CN118649186A (zh) * 2024-06-28 2024-09-17 大连医科大学附属第二医院 诃子鞣酸在制备用于治疗膀胱癌的药物中的应用
WO2026035633A1 (en) * 2024-08-06 2026-02-12 The General Hospital Corporation Compositions and methods for treating neurodegenerative diseases
GB202411739D0 (en) 2024-08-08 2024-09-25 Amazentis Sa Compositions
GB202416802D0 (en) 2024-11-14 2025-01-01 Amazentis Sa Urolithin combination
GB202417829D0 (en) 2024-12-04 2025-01-15 Amazentis Sa Formulations
CN119792272B (zh) * 2025-02-07 2025-10-03 陕西中鸿科瑞再生医学研究院有限公司 一种改善睡眠的组合物及其制备方法与制剂

Family Cites Families (101)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6479103A (en) 1987-06-09 1989-03-24 Lion Corp External preparation
JPH02304080A (ja) 1989-05-17 1990-12-17 Toyo Pharma- Kk ６Ｈ―ジベンゾ［ｂ，ｄ］ピラン―６―オン誘導体，その製法及び用途
US6066312A (en) 1996-07-16 2000-05-23 Lion Corporation Topical composition for application to the skin containing an ellagic acid-based compound or salt thereof
DE69923322T2 (de) 1998-07-30 2005-12-22 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Verwendung von propionyl-l-carnitin und acetyl-l-carnitin zur herstellung von arzneimittel mit antikrebs wirkung
KR20000019718A (ko) 1998-09-15 2000-04-15 박호군 탄닌 또는 탄닌 유래 페놀성 화합물을 포함하는 동맥경화증, 고지혈증 및 간질환의 예방 및 치료용 조성물
US20030078212A1 (en) 1998-10-30 2003-04-24 Jia-He Li Pharmaceutical compositions containing poly(adp-ribose) glycohydrolase inhibitors and methods of using the same
US7727563B2 (en) 1999-04-19 2010-06-01 Pom Wonderful, Llc Methods of using pomegranate extracts for treating diabetes related atherosclerotic complications in humans
US7611738B2 (en) 2005-05-24 2009-11-03 Pom Wonderful, Llc Processes for extracting phytochemicals from pomegranate solids and compositions and methods of use thereof
IT1306141B1 (it) * 1999-05-17 2001-05-30 Giampiero Valletta Composizione per il trattamento del prurito uremico e di forme diprurito non riconducibili a lesioni organiche.
US20010047032A1 (en) 1999-12-30 2001-11-29 Castillo Gerardo M. Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases
US6440436B1 (en) 2001-05-18 2002-08-27 Natreon Inc. Process for preparing purified shilajit composition from native shilajit
US20080039179A1 (en) 2001-06-27 2008-02-14 Seelig Jerald C Gaming display with moveable indicator and methods of use
US6953241B2 (en) 2001-11-30 2005-10-11 Brother Kogyo Kabushiki Kaisha Ink-jet head having passage unit and actuator units attached to the passage unit, and ink-jet printer having the ink-jet head
IN224411B (enExample) * 2002-08-23 2008-12-05 Dsm Ip Assets Bv
US7365193B2 (en) 2004-02-04 2008-04-29 Abbott Laboratories Amino-substituted tricyclic derivatives and methods of use
US20050171079A1 (en) 2004-02-04 2005-08-04 Schrimpf Michael R. Amino-substituted tricyclic derivatives and methods of use
ES2543981T3 (es) 2004-03-24 2015-08-26 The Regents Of The University Of California Purificaciones de elagitaninos
US20050282781A1 (en) 2004-06-18 2005-12-22 Shibnath Ghosal Compositions of stable bioactive metabolites of docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
US20060257337A1 (en) * 2005-04-28 2006-11-16 David Sherris Compositions and methods to treat skin diseases characterized by cellular proliferation and angiogenesis
US8475776B2 (en) 2005-04-28 2013-07-02 Paloma Pharmaceuticals, Inc. Compositions and methods to treat diseases characterized by cellular proliferation and angiogenesis
ES2646177T3 (es) 2006-04-26 2017-12-12 The Regents Of The University Of California Usos terapéuticos de las urolitinas
US8894993B2 (en) * 2006-08-04 2014-11-25 Natreon Inc. Mitochondria-targeted antioxidants
US8017147B2 (en) 2008-04-07 2011-09-13 Mazed Mohammad A Nutritional supplement for the prevention of cardiovascular disease, alzheimer's disease, diabetes, and regulation and reduction of blood sugar and insulin resistance
US8367072B2 (en) 2006-12-08 2013-02-05 Polifenoles Naturales, S.L. Composition for treating obesity and method of using the same
US7972633B2 (en) 2007-02-07 2011-07-05 Applied Cognitive Sciences, LLC Nutritional supplements for healthy memory and mental function
US20100298249A1 (en) * 2007-05-11 2010-11-25 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
US20110263521A1 (en) * 2007-05-11 2011-10-27 Marc Moutet Pharmaceutical or cosmetic preparations for topical and/or parenteral application, preparation methods thereof and use of same
WO2009002913A1 (en) * 2007-06-22 2008-12-31 Avicena Group, Inc. Use of creatine compounds to treat dermatitis
EP2033526A1 (en) 2007-09-07 2009-03-11 Probelte Pharma, S.A. Nutritional products comprising pomegranate extracts containing ellagitannins and their use
TW200929211A (en) 2007-12-17 2009-07-01 Etron Technology Inc Method of reducing current of memory in self-refreshing mode
AU2008345225A1 (en) * 2007-12-21 2009-07-09 University Of Rochester Method for altering the lifespan of eukaryotic organisms
WO2009120799A2 (en) 2008-03-25 2009-10-01 Paloma Pharmaceuticals, Inc. Methods of treating fibrotic disorders
US7927633B2 (en) 2008-03-28 2011-04-19 Janiece Diane Swilling Adaptogenic tea
WO2009153652A2 (en) 2008-06-19 2009-12-23 Avesthagen Limited An extract and a process thereof (pomplex)
US20100004334A1 (en) 2008-07-01 2010-01-07 Mead Johnson Nutrition Company Nutritional Compositions Containing Punicalagins
CN101301319A (zh) 2008-07-09 2008-11-12 中国科学院新疆理化技术研究所 石榴花多酚的制备方法及其应用
US20100055247A1 (en) 2008-08-29 2010-03-04 Tirrito Salvatore J Nutritional Compositions for Athletes
WO2010118419A2 (en) * 2009-04-10 2010-10-14 Haiyan Qi Novel anti-aging agents and methods to identify them
JP5385686B2 (ja) 2009-06-05 2014-01-08 サントリーホールディングス株式会社 血小板凝集抑制剤
WO2011011721A2 (en) 2009-07-24 2011-01-27 Amazentis Sa Compounds, compositions and methods for protecting brain health in neurodegenerative disorders
MX371022B (es) 2010-12-08 2020-01-13 Georgia Pacific Nonwovens Llc Material de limpieza no tejido dispersable.
CN113142581B (zh) 2010-12-23 2025-07-22 阿马曾提斯公司 用于改善线粒体功能的组合物和方法
WO2012103487A1 (en) 2011-01-27 2012-08-02 New York University Coumarin compounds as melanogenesis modifiers and uses thereof
US9381187B2 (en) 2011-02-16 2016-07-05 Paloma Pharmaceuticals, Inc. Radiation countermeasure agents
EP2678012A1 (en) 2011-02-22 2014-01-01 Institut National de la Santé et de la Recherche Medicale C-glucosidic ellagitannin compounds for use for altering the supramolecular arrangement of actin and for the treatment of osteoporosis, cancer, bacterial infection and viral infection
PT2866804T (pt) 2012-06-27 2023-12-18 Amazentis Sa Melhoria da autofagia ou aumento da longevidade por administração de urolitinas ou seus precursores
CA2972013C (en) 2013-12-23 2020-04-28 Amazentis Sa Process-scale synthesis of urolithins
GB201323008D0 (en) 2013-12-24 2014-02-12 Amazentis As Compounds and uses thereof
ES2886555T3 (es) 2014-10-02 2021-12-20 Natreon Inc Promoción de la construcción y reparación muscular y tratamiento de trastornos relacionados con el colágeno y las proteínas pertinentes mediante el uso de Shilajit
US10111842B2 (en) 2014-12-31 2018-10-30 University Of Oslo Eutectic solvents and uses thereof
JP2016216378A (ja) 2015-05-15 2016-12-22 公立大学法人岡山県立大学 ウロリチン類を含有する抗糖化剤
JP2017007951A (ja) 2015-06-17 2017-01-12 公立大学法人岡山県立大学 ウロリチンを含有する光老化抑制剤
JP2017014154A (ja) 2015-07-01 2017-01-19 公立大学法人岡山県立大学 ウロリチン類を含有するヒアルロン酸産生促進剤
JP6799767B2 (ja) 2015-07-07 2020-12-16 公立大学法人岡山県立大学 ウロリチン類を含有するメラニン産生抑制剤
JP2017031108A (ja) 2015-08-04 2017-02-09 公立大学法人岡山県立大学 ウロリチン類を含有する、抗しわ剤、コラーゲン産生促進剤、ｍｍｐ−１産生抑制剤、及びエラスターゼ活性阻害剤
GB201515391D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
GB201515387D0 (en) 2015-08-28 2015-10-14 Amazentis Sa Compositions
WO2017069216A1 (ja) 2015-10-22 2017-04-27 旭硝子株式会社 配線基板の製造方法
EP3393467B1 (en) 2015-12-24 2020-07-01 Amazentis SA Compositions comprising nicotinamide riboside and a urolithin
US11066381B2 (en) 2016-02-02 2021-07-20 Daicel Corporation Urolithins-containing aqueous solution, dried solid composition thereof and production method therefor, and urolithins stabilizing method
DE202016102778U1 (de) 2016-05-25 2017-08-28 Bobst Bielefeld Gmbh Klapplager
EP4553071A3 (en) 2017-03-08 2025-07-23 Amazentis SA Methods for improving mitophagy in subjects
EP3592347A1 (en) 2017-03-08 2020-01-15 Amazentis SA Skin treatment methods
US11969408B2 (en) 2017-03-08 2024-04-30 Amazentis Sa Method for improving mitophagy in subjects
US20180296464A1 (en) 2017-04-17 2018-10-18 W Skincare, LLC Autophagy activation nutrient complex, compositions and methods
US10485363B2 (en) 2017-05-21 2019-11-26 Go Smart, Inc. Inflatable pillow with adjustable height
DE102017131226A1 (de) 2017-12-22 2019-06-27 Dewertokin Gmbh Elektromotorischer Möbelantrieb, Möbel und Verfahren zum Erfassen einer Position eines elektromotorischen Möbelantriebs
CN112074510A (zh) 2018-02-27 2020-12-11 阿马曾提斯公司 尿石素a的工业规模合成
MX2020011619A (es) 2018-04-30 2021-01-15 Amazentis Sa Urolitina como mejorador inmunitario.
MX2020010287A (es) 2018-05-28 2020-10-16 Lm Wind Power Int Tech Ii Aps Elemento de conexion para un sistema de proteccion contra rayos de un aspa de turbina eolica.
US12288430B2 (en) 2018-07-09 2025-04-29 Shimano Inc. Information processing device
US20200085895A1 (en) 2018-09-13 2020-03-19 Verdure Sciences Punicalagin compositions and methods for the treatment of disorders arising from methylglyoxal-induced dna damage
CN109316478A (zh) 2018-11-06 2019-02-12 上海出入境检验检疫局动植物与食品检验检疫技术中心 一种尿石素a在制备抗衰老的药物、化妆品中的应用及药物、化妆品
DE112020000549B4 (de) 2019-01-28 2025-11-06 KYOCERA AVX Components Corporation (n. d. Ges. d. Staates Delaware) Mehrschichtiger Keramikkondensator mit Ultrabreitbandleistungsfähigkeit und Verfahren zur Herstellung
CN110244079B (zh) 2019-07-18 2019-12-20 西南石油大学 一种控缝高上浮剂上浮速率的测试方法
GB201910450D0 (en) 2019-07-22 2019-09-04 Iiaa Ltd Cosmetic compositions
US11016804B2 (en) 2019-08-02 2021-05-25 Argo AI, LLC Ahead of time scheduling process for autonomous vehicles
GB201912107D0 (en) 2019-08-22 2019-10-09 Amazentis Sa Combination
CN110368476A (zh) 2019-08-29 2019-10-25 中南大学湘雅医院 一种治疗骨肉瘤的手术辅助药物
GB201916046D0 (en) 2019-11-04 2019-12-18 Amazentis Sa Diagnostic method
DE102020200633A1 (de) 2020-01-21 2021-07-22 Jungheinrich Aktiengesellschaft Doppelpedalsystem für ein Flurförderzeug
US11205053B2 (en) 2020-03-26 2021-12-21 International Business Machines Corporation Semantic evaluation of tentative triggers based on contextual triggers
EP4153306A4 (en) 2020-05-22 2024-06-26 Ilera Derm LLC Compositions for treating acne and dermatological conditions
JP7838589B2 (ja) 2021-01-20 2026-04-01 味の素株式会社 化粧料組成物
CN112843049A (zh) 2021-02-02 2021-05-28 邯郸制药股份有限公司 一种组合物用于制备基于调控CDKs和SMAD6基因抑制胃癌细胞增殖药物的用途
CN113171319B (zh) 2021-05-07 2022-03-08 宝萃生物科技有限公司 一种即时、长效抗衰除皱的复合植物提取物及其制备方法和应用
CN113476362B (zh) 2021-06-23 2022-09-13 植物医生(广东)生物科技有限公司 一种面部皮肤角质更新促进剂及其应用
ES3066679T3 (en) 2021-08-30 2026-05-14 Amazentis Sa Treating long covid-19 with urolithins
CN113855758A (zh) 2021-11-02 2021-12-31 顾佳圻 一种益寿补钙丸及其制备方法
US20230277669A1 (en) 2022-02-24 2023-09-07 Amazentis Sa Uses of urolithins
AU2023237544A1 (en) 2022-03-22 2024-10-31 Amazentis Sa Compositions
CN114794490B (zh) 2022-05-25 2023-07-25 江南大学 一种具有抗皮肤光老化及辅助减脂功能的组合物
JP2025521186A (ja) 2022-06-06 2025-07-08 アマゼンティス エスアー 心臓機能および健康を改善するためのウロリチン
AU2024279527A1 (en) 2023-05-26 2026-01-15 Amazentis Sa Urolithin for improving performance in elite and sub-elite athletes
WO2024246601A1 (en) 2023-05-26 2024-12-05 Amazentis Sa Compositions comprising trigonelline and urolithin
GB202312220D0 (en) 2023-08-09 2023-09-20 Amazentis Sa Formulation
CN116889583B (zh) 2023-08-26 2024-07-23 琛蓝(美国)营养制品股份有限公司 一种富含稀有人参皂苷的人参提取物的制备方法及其应用
FR3153998A1 (fr) 2023-10-13 2025-04-18 L'oreal Utilisation cosmétique d’iso-urolithine A sur une peau sensible
EP4791374A1 (en) 2023-10-13 2026-08-19 L'oreal Cosmetic use of at least urolithin b or c on a sensitive skin
GB202316295D0 (en) 2023-10-24 2023-12-06 Amazentis Sa Composition
GB202319994D0 (en) 2023-12-22 2024-02-07 Amazentis Sa Compositions for use

Also Published As

Publication number Publication date
US20180015069A1 (en) 2018-01-18
KR102317160B1 (ko) 2021-10-25
SG11201408539UA (en) 2015-01-29
MX2014016044A (es) 2015-05-12
US20230233523A1 (en) 2023-07-27
JP7339296B2 (ja) 2023-09-05
CA3291904A1 (en) 2026-03-02
MX378354B (es) 2025-03-10
US20250228816A1 (en) 2025-07-17
ES2968368T3 (es) 2024-05-09
US9962366B2 (en) 2018-05-08
US12576065B2 (en) 2026-03-17
SG10201610798QA (en) 2017-02-27
AU2018202407A1 (en) 2018-04-26
SG10202106329TA (en) 2021-07-29
JP2025161884A (ja) 2025-10-24
EP2866804B1 (en) 2023-09-13
AR091604A1 (es) 2015-02-18
MX2022007264A (es) 2022-07-13
US12544358B2 (en) 2026-02-10
CN110934863A (zh) 2020-03-31
CA3127211A1 (en) 2014-01-03
JP2015523362A (ja) 2015-08-13
EP4233858A1 (en) 2023-08-30
JP6879980B2 (ja) 2021-06-02
AU2022200876A1 (en) 2022-03-03
KR20230116091A (ko) 2023-08-03
US20250228817A1 (en) 2025-07-17
US20210353591A1 (en) 2021-11-18
JP2021119180A (ja) 2021-08-12
MX2020008468A (es) 2022-06-14
KR20150036224A (ko) 2015-04-07
WO2014004902A2 (en) 2014-01-03
US20140018415A1 (en) 2014-01-16
CN105142632A (zh) 2015-12-09
US20230390238A1 (en) 2023-12-07
EP4566677A2 (en) 2025-06-11
US20260207549A1 (en) 2026-07-23
AU2024259763A1 (en) 2024-11-21
JP6422163B2 (ja) 2018-11-14
KR102163091B1 (ko) 2020-10-08
JP2018184455A (ja) 2018-11-22
US20160000753A1 (en) 2016-01-07
ES3032009T3 (en) 2025-07-14
BR112014032809A2 (pt) 2017-06-27
PT4233858T (pt) 2025-05-15
US11020373B2 (en) 2021-06-01
AU2013284419A1 (en) 2015-02-12
US11931336B2 (en) 2024-03-19
EP2866804A2 (en) 2015-05-06
AU2018200791A1 (en) 2018-02-22
KR20210128511A (ko) 2021-10-26
CA3127211C (en) 2026-04-07
WO2014004902A3 (en) 2014-03-06
JP2023107934A (ja) 2023-08-03
CA2877718A1 (en) 2014-01-03
BR112014032809A8 (pt) 2021-06-22
CA2877718C (en) 2021-10-12
AU2020200420B2 (en) 2021-11-11
PT2866804T (pt) 2023-12-18
MX393128B (es) 2025-03-24
AU2018202407B2 (en) 2019-11-21
DK4233858T3 (da) 2025-05-12
KR20200116176A (ko) 2020-10-08
KR20260056322A (ko) 2026-04-24
AU2020200420A1 (en) 2020-03-05
US20250375415A1 (en) 2025-12-11
CN105142632B (zh) 2020-01-07
EP4566677A3 (en) 2025-09-03
AU2022200876B2 (en) 2024-08-15
AU2018200791B2 (en) 2019-10-31
US11931335B2 (en) 2024-03-19
US20200397748A1 (en) 2020-12-24
EP4233858B1 (en) 2025-02-12

Similar Documents

Publication Publication Date Title
SG10201610798QA (en) Enhancing autophagy or increasing longevity by administration of urolithins or precursors thereof
ZA201703992B (en) Inhalable pharmaceutical compositions
PL2647387T3 (pl) Kompozycja szczepionki
SG10201912291YA (en) Vaccine compositions
ZA201406082B (en) Use of ccr3-inhibitors
GB2502767B (en) Cannula
IL266415A (en) Innovative pharmaceutical composition
GB201205164D0 (en) Pharmaceutical compounds
GB201501016D0 (en) Preparation of 18F-fluciclovine
PL2644073T3 (pl) Ssawka
GB201205189D0 (en) Novel medical use
GB201420971D0 (en) Therapeutic composition
GB201118334D0 (en) Novel dosage form
EP2712317A4 (en) PREVENTION OF INFECTIONS
IL239512A0 (en) Pharmaceutical compounds
GB201202027D0 (en) Pharmaceutical compounds
IL236873A0 (en) therapeutic compounds
GB201218407D0 (en) Adjuvants
GB201104632D0 (en) Use of medicament
GB201214237D0 (en) Novel therapeutic composition
GB201223187D0 (en) Formula 1- 2050
GB201222981D0 (en) Formula 1 -2050
GB201222964D0 (en) Formula 1 - 2050
ES2439617B1 (es) Composicion para la administracion intradermica de alergoides
GB201223115D0 (en) Drapery hardware